Navigation Links
Alseres Pharmaceuticals, Inc. Raises $5 Million
Date:3/20/2008

Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. Cethrin(R), a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. The Company's lead molecular imaging product candidate is ALTROPANE(R) which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Safe Harbor

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Alseres' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the development and commercialization of ALTROPANE and Cethrin, the prospects of the Company's CNS therapeutics program, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "co
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
2. Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation
3. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
4. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
5. Renhuang Pharmaceuticals, Inc. Retains CCG Elite
6. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
7. Jazz Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 13, 2008
8. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
9. Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR
10. Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR
11. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2015)... " Bubbly Walrus ” was featured on NewsWatch as part ... latest and coolest applications on the market for iOS, Android, ... expert, conducted the app review and shared with viewers how ... games to play on smartphones are the ones that get ... with a video game that just absorbs attention, why not ...
(Date:5/3/2015)... Mateo, CA (PRWEB) May 03, 2015 ... service, MnemeTherapy® at two upcoming area seminars. The first ... the PSA Annual Regional Stroke Conference to be held ... be offered on Wednesday, May 13 during the Dementia ... Plaza. , “These seminars offer an excellent opportunity ...
(Date:5/2/2015)... As one of only 30 Illinois ... and Health Achievement and Recognition Program (SHARP) certification, ... by the Illinois Department of Labor to host this ... SHARP certification by the Occupational Safety and Health Administration’s ... continued to meet or exceed all of the necessary ...
(Date:5/2/2015)... 02, 2015 ProText Kinetic 2 is a ... Final Cut Pro X. ProText Kinetic 2 features 40 ... Final Cut Pro X . Easily create interactive text ... Film Studios' ProText Kinetic 2. , Using ProText Kinetic is ... two ProText Kinetic presets in the FCPX timeline. Playback ...
(Date:5/2/2015)... Ohio (PRWEB) May 02, 2015 On ... Liverpool City Hospital (ELCH) gathered to celebrate improvements in ... River Valley Health Partners (RVHP), had zero acquired ventilator ... urinary catheter associated infections. ELCH was also recently named ... The management team at ELCH credited the teamwork of ...
Breaking Medicine News(10 mins):Health News:An Application to Have Fun with Mathematics Was Featured on NewsWatch Television 2Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2
... Findability with Flexibility of Vivisimo,s Velocity Search Platform , ... a powerful new level of social and personalized search for ... is helping the leading UK medical website expand its offerings ... , (LOGO: http://www.newscom.com/cgi-bin/prnh/20080626/NEW046LOGO ) , ...
... MOINES, Iowa, Nov. 24 Vitech Systems Group, Inc. ... Administration System Implementation at the Iowa Public Employees, Retirement ... funds in the U.S., contracted with Vitech in 2006 ... The solution provides advanced capabilities and increases efficiency, transforming ...
... Calif. Nov. 24, 2008Researchers at the University of Southern ... for aggressive prostate cancer blocks the development of prostate ... study in the Proceedings of the National Academy ... cancer therapy for humans. , "This research has ...
... has directed KH Real Estate to issue a boil water advisory ... Township, Armstrong County, after samples taken by DEP tested positive for ... DEP received complaints from residents after two customers were hospitalized with ... testing for the bacteria. , ...
... system for advanced radiation therapy, today announced that Rafael (Ralph) Vaello ... December 1, 2008. Mr. Vaello, who will report to TomoTherapy CEO ... sales and field marketing group for Philips Healthcare’s Oncology Imaging division. ... ...
... million of them currently abstain from alcohol, drugs , , ... million Americans over the age of 12 participate in ... including 2.3 million who currently abstain from use of ... released Monday by the federal Substance Abuse and Mental ...
Cached Medicine News:Health News:Vivisimo Helps OnMedica Deliver Personalized Search and Extend Social Search to Public-Facing Health Portal 2Health News:Vivisimo Helps OnMedica Deliver Personalized Search and Extend Social Search to Public-Facing Health Portal 3Health News:Vitech's V3 Pension Administration Software Improves IPERS' Business 2Health News:USC researchers identify novel approach for suppressing prostate cancer development 2Health News:Pennsylvania DEP Directs Shadyside Water Supply to Issue Boil Water Advisory 2Health News: TomoTherapy Names Rafael Vaello Vice President of Global Sales : Former Philips Healthcare executive brings proven sales experience in oncology, imaging industries 2Health News:5 Million People a Year Use Self-Help Addiction Programs 2
(Date:5/1/2015)... At the American Association of Neurological Surgeons ... D.C. , Elekta will highlight Leksell Gamma ... leverage the enormous amount of data – generated by ... – to advance clinical research and further optimize patient ... solution that allows practitioners to store, retrieve, and analyze ...
(Date:5/1/2015)... 2015 Pharmacyclics, Inc. (the "Company") (NASDAQ: ... ended March 31, 2015, as well as general business ... conference call will be held. Key Highlights ... 31, 2015 increased to $206 million from $119 million ... Worldwide IMBRUVICA ® (ibrutinib) net product revenue of ...
(Date:5/1/2015)... -- Cambrex Corporation (NYSE: CBM ) reports results for ... Highlights , Sales increased 18% compared to the ... impact, driven by Innovator products and Controlled Substances. , ... first quarter of 2014. , GAAP Diluted EPS from ... last year and Adjusted Diluted EPS was $0.29 compared to ...
Breaking Medicine Technology:Elekta to showcase Leksell Gamma Knife Registry at AANS Annual Meeting 2Elekta to showcase Leksell Gamma Knife Registry at AANS Annual Meeting 3Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 2Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 3Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 4Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 5Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 6Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 7Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 8Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 9Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 10Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 11Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 12Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 13Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 14Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 15Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 16Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 17Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 18Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 19Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 20Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 21Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 22Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 23Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 24Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 25Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 26Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 27Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 28Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 29Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 30Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 31Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 32Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 33Cambrex Reports First Quarter 2015 Financial Results 2
... today announced that the United States Food and ... Drug application (IND) to commence clinical trials advancing ... acute breakthrough seizures.   Following initial pre-IND discussions with ... based upon the encouraging human pharmacokinetic results seen ...
... 2012  Genomic Health, Inc. (Nasdaq: GHDX ) today ... goal of improving the quality of diagnosis, communication and support ... and rare genetic conditions.   The subsidiary is expected to be ... service in 2013.  The new venture will be led by ...
Cached Medicine Technology:Neurelis Announces FDA Allowance of IND Application for NRL-1, a Novel Intranasal Diazepam Formulation 2Genomic Health Announces Formation of New Genetics Subsidiary 2Genomic Health Announces Formation of New Genetics Subsidiary 3Genomic Health Announces Formation of New Genetics Subsidiary 4
... CIC are formed as a host ... cleared by phagocytosis. If not cleared, CIC ... inflammatory response. CIC are increased in Systemic ... may be involved in other autoimmune disorders ...
Microalbumin Linearity Control...
The K-ASSAY Lipid Controls are assayed controls produced from fresh human sera to monitor the accuracy and precision of quantitative lipid determinations of human sera specimens....
... ASO / RF / CRP ... be used as a consistent ... for monitoring the performance of ... Factor (RF), and C-Reactive Protein ...
Medicine Products: